Amgen’s (Nasdaq: AMGN) experimental migraine drug erenumab has met the main goal of a midstage study by reducing the number of monthly attacks compared with a placebo.
Erenumab, which is being co-developed with Novartis (VTX: NOVN), was tested at two doses in a 12-week, 667-patient Phase II study of subjects who were experiencing about 18 migraine days a month.
Patients who received either the 70mg or 140mg doses injected once monthly experienced a 6.6-day reduction in monthly migraine days, according to initial results.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze